<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306527</url>
  </required_header>
  <id_info>
    <org_study_id>V58P4E1</org_study_id>
    <secondary_id>EUDRACT: 2005-001902-26</secondary_id>
    <nct_id>NCT00306527</nct_id>
  </id_info>
  <brief_title>Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines and Diagnostics S.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset)
      following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells
      or in embryonated hen eggs, in healthy adult and elderly subjects who received either vaccine
      one year before (2004) in the study V58P4.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine</measure>
    <time_frame>Day 1 to Day 7 postvaccination</time_frame>
    <description>To assess the safety and tolerability in terms of number of adult and elderly subjects reporting solicited adverse events following one dose of the cTIV or the TIV vaccine .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six-months Safety Data of Subjects After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</measure>
    <time_frame>Upto 6 months postvaccination</time_frame>
    <description>To collect additional safety data for 6 months after vaccination with one dose of cell culture derived or egg-derived influenza vaccine in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician's visit and/or resulting in premature subject's withdrawal from study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>The haemagglutinin inhibition (HI) antibody titer response following one 0.5 mL dose of either cell derived (cTIV) or egg-derived vaccine (TIV) in adult and elderly subjects is reported as GMTs.
The HI GMTs were evaluated using egg-derived antigen assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMRs), After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of GMR in adult and elderly subjects following one 0.5ml dose of either the cTIV vaccine or the TIV vaccine, according to the CHMP criteria.
The European licensure (CHMP) criteria was met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Adult and Elderly Subjects Achieving HI Titers ≥ 40 After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine.</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects achieving HI titers≥40,after one dose of either the cTIV vaccine or the TIV vaccine.
European (CHMP) criteria is met if the percentage of subjects achieving HI titers ≥ 40 is &gt; 70% for adults and &gt;60% for elderly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Adult and Elderly Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</measure>
    <time_frame>Day 22 postvaccination</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects showing seroconversion or significant increase in HI antibody titers after one dose of cell culture-derived or the egg-derived influenza vaccine.
Seroconversion or significant increase as per European Licensure (CHMP) criteria is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥ 40 for adults and ≥ 30 for elderly. Significant increase is defined as percentage of subjects with a prevaccination HI titer ≥ 10 and a ≥ 4-fold increase in postvaccination HI antibody titer.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2235</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>cTIV\cTIV (adults)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV\TIV (adults)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV\cTIV (elderly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV\TIV (elderly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV\TIV (adults)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV\cTIV (adults)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV\TIV (elderly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV\cTIV (elderly)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture derived influenza vaccine</intervention_name>
    <description>as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm</description>
    <arm_group_label>cTIV\cTIV (adults)</arm_group_label>
    <arm_group_label>cTIV\cTIV (elderly)</arm_group_label>
    <arm_group_label>TIV\cTIV (adults)</arm_group_label>
    <arm_group_label>TIV\cTIV (elderly)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>egg-derived influenza subunit vaccine</intervention_name>
    <description>as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm</description>
    <arm_group_label>cTIV\TIV (adults)</arm_group_label>
    <arm_group_label>cTIV\TIV (elderly)</arm_group_label>
    <arm_group_label>TIV\TIV (adults)</arm_group_label>
    <arm_group_label>TIV\TIV (elderly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to &lt; 61 years of age (first age group) OR 61 years of age and older (second age
             group) at enrolment in V58P4

          2. Mentally competent to understand the nature, the scope and the consequences of the
             study

          3. Able and willing to give written informed consent prior to study entry

          4. Available for all the visits scheduled in the study

          5. in good health as determined by:

               1. Medical history related to the previous six months,

               2. Physical examination,

               3. Clinical judgment of the investigator.

        Exclusion Criteria:

          1. Unwilling or unable to give written informed consent to participate in the study

          2. Currently experiencing an acute infectious disease

          3. Any serious disease such as, for example:

               1. Cancer (except for benign or localized skin cancer and non metastatic prostate
                  cancer not currently treated with chemotherapy)

               2. Autoimmune disease (including rheumatoid arthritis)

               3. Advanced arteriosclerotic disease or complicated diabetes mellitus

               4. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy

               5. Acute or progressive hepatic disease

               6. Acute or progressive renal disease

               7. Congestive heart failure

          4. Surgery planned during the study period

          5. Bleeding diathesis

          6. History of hypersensitivity to any component of the study medication or chemically
             related substances, such as allergy to eggs or egg products

          7. Known or suspected impairment/alteration of immune function resulting from:

               1. Receipt of immunosuppressive therapy (any cortical steroid or cancer
                  chemotherapy)

               2. Receipt of immunostimulants

               3. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within the past 3 months and for the full length of the study

               4. High risk for developing an immunocompromising disease

          8. History of drug or alcohol abuse

          9. Laboratory confirmed influenza disease in the past 6 months

         10. Received influenza vaccine within the past 6 months

         11. Received another vaccine or any investigational agent within the past 60 days, or
             expect to receive another vaccine within 3 weeks following the study vaccination

         12. Participation in another clinical trial within 90 days prior to enrollment and
             throughout the full length of the study

         13. Any acute respiratory disease or infections requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or
             experienced fever _ 38°C within the past 5 days

         14. Pregnant/ breast feeding women or women who refuse to use a reliable contraceptive
             method during the first three weeks after vaccination

         15. Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wojewódzki Szpital Dzieci_cy</name>
      <address>
        <city>ul. Langiewicza 2</city>
        <state>Kielce</state>
        <zip>25-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Bada_ Farmakologii Klinicznej</name>
      <address>
        <city>ul. Ujastek 3</city>
        <state>Krakow</state>
        <zip>30-969</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Jagiello_skie</name>
      <address>
        <city>Centrum Medyczne Sp. z o.o., o_. Jagiello_skie 1</city>
        <state>Kraków</state>
        <zip>31-832</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Praktyka Grupowa Lekarzy Rodzinnych, &quot;Familia&quot; Sp. z o.o.</name>
      <address>
        <city>Pl. Sikorskiego 6a</city>
        <state>Kraków</state>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Jana Pawła II, Oddz. Neuroinfekcji</name>
      <address>
        <city>ul. Pr_dnicka 80</city>
        <state>Kraków</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Casula D, Sparacio M, Kovacs C, Groth N. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. Hum Vaccin Immunother. 2012 May;8(5):645-52. doi: 10.4161/hv.19493. Epub 2012 May 1.</citation>
    <PMID>22418809</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>December 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2013</results_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>adult/elderly</keyword>
  <keyword>flu cell culture</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 5 study centers in Poland.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adults (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects (18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="P2">
          <title>Adults (cTIV\TIV) + (TIV\TIV)</title>
          <description>Subjects (18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
        <group group_id="P3">
          <title>Elderly (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects(≥61years of age ) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="P4">
          <title>Elderly (cTIV\TIV) + (TIV\TIV)</title>
          <description>Subjects (≥61years) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
                <participants group_id="P2" count="534"/>
                <participants group_id="P3" count="572"/>
                <participants group_id="P4" count="596"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="527"/>
                <participants group_id="P2" count="527"/>
                <participants group_id="P3" count="567">Additional death has been reported post study. Please refer to outcome measure-2.</participants>
                <participants group_id="P4" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adults (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects(18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine, received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="B2">
          <title>Elderly (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects(≥61 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine, received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="B3">
          <title>Adults (cTIV\TIV) + (TIV\TIV)</title>
          <description>Subjects (18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
        <group group_id="B4">
          <title>Elderly (cTIV\TIV) + (TIV\TIV)</title>
          <description>Subjects (≥61 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="533"/>
            <count group_id="B2" value="572"/>
            <count group_id="B3" value="534"/>
            <count group_id="B4" value="596"/>
            <count group_id="B5" value="2235"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="12.7"/>
                    <measurement group_id="B2" value="69.2" spread="5.7"/>
                    <measurement group_id="B3" value="39.0" spread="12.5"/>
                    <measurement group_id="B4" value="69.9" spread="5.7"/>
                    <measurement group_id="B5" value="55.2" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="309"/>
                    <measurement group_id="B4" value="353"/>
                    <measurement group_id="B5" value="1278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="243"/>
                    <measurement group_id="B5" value="957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Six-months Safety Data of Subjects After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</title>
        <description>To collect additional safety data for 6 months after vaccination with one dose of cell culture derived or egg-derived influenza vaccine in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician’s visit and/or resulting in premature subject’s withdrawal from study.</description>
        <time_frame>Upto 6 months postvaccination</time_frame>
        <population>This analysis was done on the safety dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Six-months Safety Data of Subjects After One Dose of Cell Culture Derived or Egg-derived Influenza Vaccine</title>
          <description>To collect additional safety data for 6 months after vaccination with one dose of cell culture derived or egg-derived influenza vaccine in terms of serious adverse events (SAEs), adverse events (AEs) necessitating a physician’s visit and/or resulting in premature subject’s withdrawal from study.</description>
          <population>This analysis was done on the safety dataset.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="297"/>
                <count group_id="O5" value="260"/>
                <count group_id="O6" value="261"/>
                <count group_id="O7" value="300"/>
                <count group_id="O8" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</title>
        <description>The haemagglutinin inhibition (HI) antibody titer response following one 0.5 mL dose of either cell derived (cTIV) or egg-derived vaccine (TIV) in adult and elderly subjects is reported as GMTs.
The HI GMTs were evaluated using egg-derived antigen assay.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>The analysis was done on the immunogenicity subset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</title>
          <description>The haemagglutinin inhibition (HI) antibody titer response following one 0.5 mL dose of either cell derived (cTIV) or egg-derived vaccine (TIV) in adult and elderly subjects is reported as GMTs.
The HI GMTs were evaluated using egg-derived antigen assay.</description>
          <population>The analysis was done on the immunogenicity subset.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="28" upper_limit="58"/>
                    <measurement group_id="O2" value="34" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="O3" value="26" lower_limit="19" upper_limit="35"/>
                    <measurement group_id="O4" value="20" lower_limit="15" upper_limit="27"/>
                    <measurement group_id="O5" value="35" lower_limit="25" upper_limit="51"/>
                    <measurement group_id="O6" value="36" lower_limit="25" upper_limit="51"/>
                    <measurement group_id="O7" value="24" lower_limit="18" upper_limit="32"/>
                    <measurement group_id="O8" value="26" lower_limit="19" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="65" upper_limit="116"/>
                    <measurement group_id="O2" value="83" lower_limit="62" upper_limit="111"/>
                    <measurement group_id="O3" value="57" lower_limit="43" upper_limit="76"/>
                    <measurement group_id="O4" value="61" lower_limit="46" upper_limit="80"/>
                    <measurement group_id="O5" value="72" lower_limit="53" upper_limit="96"/>
                    <measurement group_id="O6" value="104" lower_limit="78" upper_limit="140"/>
                    <measurement group_id="O7" value="61" lower_limit="46" upper_limit="81"/>
                    <measurement group_id="O8" value="80" lower_limit="61" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O3" value="20" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O4" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O5" value="19" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O6" value="21" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O7" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O8" value="20" lower_limit="15" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173" lower_limit="129" upper_limit="233"/>
                    <measurement group_id="O2" value="109" lower_limit="81" upper_limit="146"/>
                    <measurement group_id="O3" value="229" lower_limit="163" upper_limit="321"/>
                    <measurement group_id="O4" value="197" lower_limit="141" upper_limit="277"/>
                    <measurement group_id="O5" value="78" lower_limit="58" upper_limit="105"/>
                    <measurement group_id="O6" value="170" lower_limit="127" upper_limit="229"/>
                    <measurement group_id="O7" value="125" lower_limit="89" upper_limit="175"/>
                    <measurement group_id="O8" value="251" lower_limit="178" upper_limit="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22" upper_limit="40"/>
                    <measurement group_id="O2" value="26" lower_limit="19" upper_limit="35"/>
                    <measurement group_id="O3" value="36" lower_limit="27" upper_limit="48"/>
                    <measurement group_id="O4" value="48" lower_limit="36" upper_limit="64"/>
                    <measurement group_id="O5" value="37" lower_limit="27" upper_limit="50"/>
                    <measurement group_id="O6" value="35" lower_limit="26" upper_limit="48"/>
                    <measurement group_id="O7" value="26" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O8" value="37" lower_limit="27" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="60" upper_limit="99"/>
                    <measurement group_id="O2" value="71" lower_limit="55" upper_limit="91"/>
                    <measurement group_id="O3" value="84" lower_limit="64" upper_limit="111"/>
                    <measurement group_id="O4" value="128" lower_limit="97" upper_limit="168"/>
                    <measurement group_id="O5" value="67" lower_limit="52" upper_limit="86"/>
                    <measurement group_id="O6" value="104" lower_limit="81" upper_limit="133"/>
                    <measurement group_id="O7" value="68" lower_limit="51" upper_limit="89"/>
                    <measurement group_id="O8" value="116" lower_limit="88" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMRs), After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</title>
        <description>Immunogenicity was assessed in terms of GMR in adult and elderly subjects following one 0.5ml dose of either the cTIV vaccine or the TIV vaccine, according to the CHMP criteria.
The European licensure (CHMP) criteria was met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>The analysis was done on the immunogenicity subset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMRs), After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in Adult and Elderly Subjects</title>
          <description>Immunogenicity was assessed in terms of GMR in adult and elderly subjects following one 0.5ml dose of either the cTIV vaccine or the TIV vaccine, according to the CHMP criteria.
The European licensure (CHMP) criteria was met if the mean geometric increase (GMR, day 22/day 1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
          <population>The analysis was done on the immunogenicity subset.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="1.67" upper_limit="2.74"/>
                    <measurement group_id="O2" value="2.46" lower_limit="1.92" upper_limit="3.15"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.71" upper_limit="2.84"/>
                    <measurement group_id="O4" value="2.98" lower_limit="2.31" upper_limit="3.84"/>
                    <measurement group_id="O5" value="2.02" lower_limit="1.58" upper_limit="2.6"/>
                    <measurement group_id="O6" value="2.91" lower_limit="2.27" upper_limit="3.73"/>
                    <measurement group_id="O7" value="2.54" lower_limit="1.97" upper_limit="3.28"/>
                    <measurement group_id="O8" value="3.11" lower_limit="2.41" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.13" upper_limit="14"/>
                    <measurement group_id="O2" value="6.17" lower_limit="4.64" upper_limit="8.2"/>
                    <measurement group_id="O3" value="12" lower_limit="8.49" upper_limit="16"/>
                    <measurement group_id="O4" value="7.64" lower_limit="5.58" upper_limit="10"/>
                    <measurement group_id="O5" value="4.09" lower_limit="3.07" upper_limit="5.45"/>
                    <measurement group_id="O6" value="8.05" lower_limit="6.06" upper_limit="11"/>
                    <measurement group_id="O7" value="6.59" lower_limit="4.81" upper_limit="9.04"/>
                    <measurement group_id="O8" value="12" lower_limit="8.94" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="2.07" upper_limit="3.29"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.14" upper_limit="3.41"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.86" upper_limit="3.03"/>
                    <measurement group_id="O4" value="2.67" lower_limit="2.09" upper_limit="3.42"/>
                    <measurement group_id="O5" value="1.81" lower_limit="1.43" upper_limit="2.29"/>
                    <measurement group_id="O6" value="2.93" lower_limit="2.32" upper_limit="3.7"/>
                    <measurement group_id="O7" value="2.64" lower_limit="2.07" upper_limit="3.38"/>
                    <measurement group_id="O8" value="3.19" lower_limit="2.5" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Adult and Elderly Subjects Achieving HI Titers ≥ 40 After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
        <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects achieving HI titers≥40,after one dose of either the cTIV vaccine or the TIV vaccine.
European (CHMP) criteria is met if the percentage of subjects achieving HI titers ≥ 40 is &gt; 70% for adults and &gt;60% for elderly.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>This analysis was done on immunogenicity subset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Adult and Elderly Subjects Achieving HI Titers ≥ 40 After One Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
          <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects achieving HI titers≥40,after one dose of either the cTIV vaccine or the TIV vaccine.
European (CHMP) criteria is met if the percentage of subjects achieving HI titers ≥ 40 is &gt; 70% for adults and &gt;60% for elderly.</description>
          <population>This analysis was done on immunogenicity subset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="43" upper_limit="69"/>
                    <measurement group_id="O2" value="48" lower_limit="35" upper_limit="62"/>
                    <measurement group_id="O3" value="49" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="O4" value="36" lower_limit="24" upper_limit="49"/>
                    <measurement group_id="O5" value="54" lower_limit="41" upper_limit="67"/>
                    <measurement group_id="O6" value="57" lower_limit="43" upper_limit="69"/>
                    <measurement group_id="O7" value="36" lower_limit="24" upper_limit="49"/>
                    <measurement group_id="O8" value="48" lower_limit="35" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="73" upper_limit="93"/>
                    <measurement group_id="O2" value="80" lower_limit="68" upper_limit="89"/>
                    <measurement group_id="O3" value="77" lower_limit="65" upper_limit="87"/>
                    <measurement group_id="O4" value="74" lower_limit="61" upper_limit="84"/>
                    <measurement group_id="O5" value="80" lower_limit="67" upper_limit="89"/>
                    <measurement group_id="O6" value="90" lower_limit="79" upper_limit="96"/>
                    <measurement group_id="O7" value="69" lower_limit="56" upper_limit="80"/>
                    <measurement group_id="O8" value="82" lower_limit="70" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="15" upper_limit="38"/>
                    <measurement group_id="O2" value="27" lower_limit="16" upper_limit="40"/>
                    <measurement group_id="O3" value="30" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="O4" value="39" lower_limit="27" upper_limit="53"/>
                    <measurement group_id="O5" value="32" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="O6" value="33" lower_limit="22" upper_limit="47"/>
                    <measurement group_id="O7" value="26" lower_limit="16" upper_limit="39"/>
                    <measurement group_id="O8" value="34" lower_limit="23" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="82" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O3" value="97" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O4" value="95" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O5" value="86" lower_limit="75" upper_limit="94"/>
                    <measurement group_id="O6" value="92" lower_limit="82" upper_limit="97"/>
                    <measurement group_id="O7" value="87" lower_limit="76" upper_limit="94"/>
                    <measurement group_id="O8" value="92" lower_limit="82" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="37" upper_limit="63"/>
                    <measurement group_id="O2" value="50" lower_limit="37" upper_limit="63"/>
                    <measurement group_id="O3" value="59" lower_limit="46" upper_limit="71"/>
                    <measurement group_id="O4" value="61" lower_limit="47" upper_limit="73"/>
                    <measurement group_id="O5" value="54" lower_limit="41" upper_limit="67"/>
                    <measurement group_id="O6" value="58" lower_limit="45" upper_limit="71"/>
                    <measurement group_id="O7" value="43" lower_limit="30" upper_limit="56"/>
                    <measurement group_id="O8" value="62" lower_limit="49" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="68" upper_limit="89"/>
                    <measurement group_id="O2" value="90" lower_limit="79" upper_limit="96"/>
                    <measurement group_id="O3" value="84" lower_limit="72" upper_limit="92"/>
                    <measurement group_id="O4" value="92" lower_limit="82" upper_limit="97"/>
                    <measurement group_id="O5" value="85" lower_limit="73" upper_limit="93"/>
                    <measurement group_id="O6" value="87" lower_limit="75" upper_limit="94"/>
                    <measurement group_id="O7" value="84" lower_limit="72" upper_limit="92"/>
                    <measurement group_id="O8" value="90" lower_limit="80" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Adult and Elderly Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
        <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects showing seroconversion or significant increase in HI antibody titers after one dose of cell culture-derived or the egg-derived influenza vaccine.
Seroconversion or significant increase as per European Licensure (CHMP) criteria is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥ 40 for adults and ≥ 30 for elderly. Significant increase is defined as percentage of subjects with a prevaccination HI titer ≥ 10 and a ≥ 4-fold increase in postvaccination HI antibody titer.</description>
        <time_frame>Day 22 postvaccination</time_frame>
        <population>This analysis was done on the immunogenicity subset.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Adult and Elderly Subjects With Seroconversion or Significant Increase in HI Antibody Titers After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine.</title>
          <description>Immunogenicity was assessed in terms of percentages of adult and elderly subjects showing seroconversion or significant increase in HI antibody titers after one dose of cell culture-derived or the egg-derived influenza vaccine.
Seroconversion or significant increase as per European Licensure (CHMP) criteria is defined as percentage of subjects with a prevaccination HI titer &lt;10 to a postvaccination titer ≥ 40 for adults and ≥ 30 for elderly. Significant increase is defined as percentage of subjects with a prevaccination HI titer ≥ 10 and a ≥ 4-fold increase in postvaccination HI antibody titer.</description>
          <population>This analysis was done on the immunogenicity subset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="12" upper_limit="34"/>
                    <measurement group_id="O2" value="32" lower_limit="20" upper_limit="45"/>
                    <measurement group_id="O3" value="30" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="O4" value="34" lower_limit="23" upper_limit="48"/>
                    <measurement group_id="O5" value="24" lower_limit="14" upper_limit="37"/>
                    <measurement group_id="O6" value="30" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="O7" value="30" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="O8" value="43" lower_limit="30" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="70" upper_limit="90"/>
                    <measurement group_id="O2" value="85" lower_limit="73" upper_limit="93"/>
                    <measurement group_id="O3" value="84" lower_limit="72" upper_limit="92"/>
                    <measurement group_id="O4" value="80" lower_limit="68" upper_limit="89"/>
                    <measurement group_id="O5" value="61" lower_limit="47" upper_limit="73"/>
                    <measurement group_id="O6" value="80" lower_limit="68" upper_limit="89"/>
                    <measurement group_id="O7" value="77" lower_limit="65" upper_limit="87"/>
                    <measurement group_id="O8" value="82" lower_limit="70" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="17" upper_limit="41"/>
                    <measurement group_id="O2" value="33" lower_limit="22" upper_limit="47"/>
                    <measurement group_id="O3" value="28" lower_limit="17" upper_limit="41"/>
                    <measurement group_id="O4" value="34" lower_limit="23" upper_limit="48"/>
                    <measurement group_id="O5" value="27" lower_limit="16" upper_limit="40"/>
                    <measurement group_id="O6" value="40" lower_limit="28" upper_limit="53"/>
                    <measurement group_id="O7" value="31" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="O8" value="41" lower_limit="29" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine</title>
        <description>To assess the safety and tolerability in terms of number of adult and elderly subjects reporting solicited adverse events following one dose of the cTIV or the TIV vaccine .</description>
        <time_frame>Day 1 to Day 7 postvaccination</time_frame>
        <population>This analysis was done on safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O2">
            <title>cTIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O3">
            <title>cTIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O4">
            <title>cTIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O5">
            <title>TIV\TIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O6">
            <title>TIV\cTIV (Adults)</title>
            <description>Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
          <group group_id="O7">
            <title>TIV\TIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.</description>
          </group>
          <group group_id="O8">
            <title>TIV\cTIV (Elderly)</title>
            <description>Subjects (≥61years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine</title>
          <description>To assess the safety and tolerability in terms of number of adult and elderly subjects reporting solicited adverse events following one dose of the cTIV or the TIV vaccine .</description>
          <population>This analysis was done on safety dataset</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="297"/>
                <count group_id="O5" value="260"/>
                <count group_id="O6" value="261"/>
                <count group_id="O7" value="300"/>
                <count group_id="O8" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="84"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="63"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="46"/>
                    <measurement group_id="O7" value="37"/>
                    <measurement group_id="O8" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home due to reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through out the study period</time_frame>
      <desc>Post-injection solicited adverse events were collected from Day 1-7. Other AEs and SAEs were collected through out the study period (Day 1 to 6 months).</desc>
      <group_list>
        <group group_id="E1">
          <title>Adults (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects(18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="E2">
          <title>Adults (cTIV/TIV) + (TIV\TIV)</title>
          <description>Subjects (18-60 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
        <group group_id="E3">
          <title>Elderly (cTIV\cTIV) + (TIV\cTIV)</title>
          <description>Subjects(≥61 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of cTIV in this study, one year later.</description>
        </group>
        <group group_id="E4">
          <title>Elderly (cTIV\TIV) + (TIV\TIV)</title>
          <description>Subjects (≥61 years of age) who previously received one dose of either cell-derived (cTIV) or egg derived (TIV) trivalent influenza vaccine received one dose of TIV in this study, one year later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Adams stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Spilgelian hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Umblical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood electrolytes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Toe deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cerebral infraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angineurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="148" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="597"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="533"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="571"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="597"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

